Ranbaxy Laboratories Limited

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Ranbaxy Laboratories Limited sits in the top decile of US sponsors by registered trial count (#407 of 15,742 sponsors by registered trial count).

44 total trials none currently recruiting 44 completed early-phase tilt top decile by trial count

Ranbaxy Laboratories Limited: 44 sponsored US clinical trials, none currently recruiting.

Ranbaxy Laboratories Limited sponsors 44 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 44 completed. 0 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 9 trials.

Top-decile sponsor footprint

Ranbaxy Laboratories Limited ranks in the top decile of sponsors by registered trial count (#407 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

A 90/100

44 of 44 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

44 total, page 1 of 1

COMPLETED Phase 1

A Bioequivalence Study Of 80 Mg Atorvastatin Calcium Tablets Versus 80 Mg Lipitor® Tablets Under Fed Conditions

NCT01499771

COMPLETED Phase 1

A Bioequivalence Study Of 80 Mg Atorvastatin Calcium Tablets Versus 80 Mg Lipitor® Tablets Under Fasting Conditions.

NCT01499758

COMPLETED Phase 1

Bioequivalence Study of Donepezil Hydrochloride 10 mg Tablets Under Fed Conditions

NCT01276080

COMPLETED Phase 1

Bioequivalence Study of Donepezil Hydrochloride 10 mg Tablets Under Fasting Conditions

NCT01276067

COMPLETED NA

Bioequivalence Study of Metformin Hydrochloride 1000mg Tablets Under Fasting Conditions

NCT00778427

COMPLETED NA

Bioequivalence Study of Metformin Hydrochloride 1000mg Tablets Under Fed Conditions

NCT00778466

COMPLETED NA

Bioequivalence Study of Furosemide 80mg Tablets Under Fasting Conditions

NCT00778180

COMPLETED NA

Bioequivalence Study of Sertraline Hydrochloride 100mg Tablets Under Fed Conditions

NCT00778973

COMPLETED NA

Bioequivalence Study of Zolpidem 10mg Tablets Under Fasting Conditions

NCT00779051

COMPLETED NA

Bioequivalence Study of Zolpidem 10 mg Tablets Under Fed Conditions

NCT00779441

COMPLETED NA

Bioequivalence Study of Sertraline Hydrochloride 100mg Tablets Under Fasting Conditions

NCT00779350

COMPLETED NA

Bioequivalence Study of Amlodipine Tablets Under Fasting Conditions

NCT00775905

COMPLETED NA

Bioequivalence Study of Amlodipine 10mg Tablets Under Fed Conditions

NCT00775151

COMPLETED NA

Bioequivalence Study of Doxycycline Monohydrate 100mg Tablets Under Fasting Conditions

NCT00775177

COMPLETED NA

Bioequivaelnce Study of Doxycycline Monohydrate 100mg Tablets Under Fed Conditions

NCT00775918

COMPLETED NA

Bioequivalence Study of Atenolol 100mg Tablets Under Fasting Conditions

NCT00775580

COMPLETED NA

Bioequivalence Study of Cetirizine Hydrochloride 10mg Tablets Under Fed Conditions

NCT00776022

COMPLETED NA

Bioequivalence Study of Loperamide Hydrochloride 2 mg and Simethicone 125 mg Tablet Under Fasting Conditions

NCT00778115

COMPLETED NA

Bioequivalence Study of Risperidone 1 mg Orally-disintegrating Tablets Under Fed Conditions

NCT01222923

COMPLETED NA

Bioequivalence Study of Benazepril HCl / Hydrochlorothiazide 20 mg/ 25 mg Tablets Under Fed Conditions

NCT00778674

COMPLETED NA

Bioequivalence Study of Risperidone 1 mg Orally-disintegrating Tablets Under Fasting Conditions

NCT01222975

COMPLETED NA

Bioequivalence Study of Cetirizine Hydrochloride 10mg Tablets Under Fasting Conditions

NCT00776139

COMPLETED NA

Bioequivalence Study of Zidovudine 300 mg Tablets, USP Under Fasting Conditions

NCT00779233

COMPLETED NA

Bioequivalence Study of Benazepril HCl / Hydrochlorothiazide 20 mg/ 25 mg Tablets Under Fasting Conditions

NCT00778726

COMPLETED NA

Bioequivalence Study of Metformin HCl 750 mg XR Under Fasting Conditions

NCT00778791

COMPLETED NA

Bioequivalence Study of Metformin HCl 750 mg XR Tablets Under Non Fasting Conditions

NCT00778141

COMPLETED NA

Bioequivalence Study of Clorazepate Dipotassium 15mg Tablets Under Fasting Conditions

NCT00775996

COMPLETED NA

Bioequivalence Study of Fluoxetine HCL 40 mg Capsules Under Fasting Conditions

NCT00778024

COMPLETED NA

Bioequivalence Study of Glimepiride 1mg Tablets Under Fed Conditions

NCT00776620

COMPLETED NA

Bioequivalence Study of Glimepiride 1mg Tablets Under Fasting Conditions

NCT00776490

COMPLETED NA

Bioequivalence Study of Fosinopril Sodium/ Hydrochlorothiazide 20/ 12.5 mg Tablets Under Fasting Conditions

NCT00777972

COMPLETED NA

Bioequivalence Study of Fosinopril Sodium / Hydrochlorothiazide 20/ 12.5 mg Tablets Under Fed Conditions

NCT00778713

COMPLETED NA

Bioequivalence Study of Clarithromycin 500mg Tablets Under Fasting Conditions.

NCT00774644

COMPLETED NA

Bioequivalence Study of Clarithromycin 500 mg Tablets Under Non-Fasting Conditions

NCT00774696

COMPLETED NA

Bioequivalecne Study of Minocycline 100mg Tablets Under Fed Conditions

NCT00777413

COMPLETED NA

Bioequivalence Study of Fosinopril 40mg Tablets Under Fasting Conditions

NCT00776334

COMPLETED NA

Bioequivalence Study of Minocycline 100mg Tablets Under Fasting Conditions

NCT00776542

COMPLETED NA

Bioequivalence Study of Fosinopril 40mg Tablets Under Fed Conditions

NCT00776672

COMPLETED NA

Bioequivalence Study of Amoxicillin 400 mg/Clavulanic Acid 57 mg Chewable Tablets Under Fed Conditions

NCT00778284

COMPLETED NA

Bioequivalence Study of Amoxicillin Dispersible 600 mg Tablets Under Fasting Conditions

NCT00778050

COMPLETED NA

Bioequivalence Study of Amoxicillin 400 mg/Clavulanic Acid 57 mg Chewable Tablets Under Fasting Conditions

NCT00778661

COMPLETED NA

Bioequivalence Study of Gabapentin 800 mg Tablets Under Fed Conditions

NCT00778232

COMPLETED NA

Bioequivalence Study of Gabapentin 800 mg Tablets Under Fasting Conditions

NCT00778401

COMPLETED NA

Bioequivalence Study of Fenofibrate 160mg Tablets Under Fed Conditions

NCT00775359

Phase Distribution

PhaseTrial count
Phase 1 4

Therapeutic Areas

How the Ranbaxy Laboratories Limited early-phase archive is shaped

44 indexed studies, none listed as recruiting (0% open); 44 completed (100%).

Phase mix: 0 late (III/IV) vs 4 early (I/II) (early-phase heavy).

Top condition: Healthy (9 trials), 0 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Ranbaxy Laboratories Limited: archived-pipeline peers nationwide

Peers matched on 44 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Ranbaxy Laboratories Limited sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 01020304050 0%2%4%6%8% Total trials Recruiting share Ranbaxy Laboratories LimitedAgios PharmaceuticalsBeth Israel Medical CenterInnovative MedicalKowa Research Institute10xBio22nd Century Group23andMe3-C Institute for Social Development
Ranbaxy Laboratories Limited sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Ranbaxy Laboratories Limited sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 44 archived trials

Sponsors with similar archive density (± trial count)

What to do with this Ranbaxy Laboratories Limited page

44 registered trials is a research-attention snapshot, not an endorsement of Ranbaxy Laboratories Limited or any single study.

  • None of Ranbaxy Laboratories Limited's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Healthy is the condition Ranbaxy Laboratories Limited studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Ranbaxy Laboratories Limited pipeline card: 44 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.